Glen Eagle Advisors, LLC Aclaris Therapeutics, Inc. Transaction History

Glen Eagle Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.01 - $1.36 $101 - $136	-100 Closed	0 $0
Q3 2019 Aug 13, 2024	SELL	$0.79 - $2.47 $79 - $247	-100 Closed	0 $0
Q1 2019 Aug 13, 2024	BUY	$5.63 - $7.84 $563 - $784	100 New	100 $599,000
Q2 2018 Aug 13, 2024	SELL	$16.46 - $20.33 $27,191 - $33,585	-1,652 Reduced 94.29%	100 $2 Million
Q1 2018 Aug 14, 2024	BUY	$17.08 - $25.64 $1,707 - $2,564	100 New	100 $1.75 Million
Q1 2018 Aug 13, 2024	BUY	$17.08 - $25.64 $28,216 - $42,357	1,652 Added 1652.0%	1,752 $1.75 Million
Q4 2017 Aug 13, 2024	BUY	$21.47 - $27.8 $2,147 - $2,780	100	100 $2.47 Million

53.7M

32.4K

3.3K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $163M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.